Yourgene Offers Premaitha An Asian Reprieve From Illumina Patent Tussle
Executive Summary
Noninvasive prenatal testing specialist Premaitha Health has agreed to acquire Taiwan's Yourgene Bioscience, enabling the UK company to expand its presence in Asia. The deal also offers an important market that has not been tainted by ongoing patent litigation between Premaitha and US next-generation sequencing firm Illumina.
You may also be interested in...
M&A Analysis: Underwhelming 2016, But Hope For 2017 US Market Boom
The last month of 2016 saw a final flurry of medtech M&A activity as companies rushed to seal deals before the New Year arrived. Medtech Insight's M&A data tracker recorded twice as many deals in December compared to the previous month, but that was not enough to boost the year's tally, which fell behind 2015.
Premaitha pushing on in spite of Illumina prenatal testing patent lawsuit
UK noninvasive prenatal testing specialist Premaitha Health has been dealt a blow after larger rival Illumina sued it for patent infringement. But while Premaitha CEO Stephen Little described the development as a “nuisance,” he is confident that the firm’s technology does not infringe any third-party IP, he told Clinica.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.